Renalytix plc announced that Timothy Scannell has stepped down from his role as independent Non-Executive Director of Renalytix effective as of October 18, 2023, to pursue other opportunities. It has been a wonderful learning experience to work alongside Tim for the past 18 months. He has been a significant contributor to Renalytix.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.25 GBX | +18.46% | +16.67% | +24.19% |
03:42pm | Renalytix's Diabetes, Kidney Disease Test Gets Medicare Final Coverage Determination | MT |
02:23pm | Renalytix Secures Medicare's Final Local Coverage Determination for Kidney Disease Test | MT |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+24.19% | 32M | |
-50.69% | 2.5B | |
+25.26% | 2B | |
-8.81% | 1.51B | |
+28.12% | 1.33B | |
-18.54% | 960M | |
-1.69% | 802M | |
-32.14% | 793M | |
-24.10% | 640M | |
+19.34% | 577M |
- Stock Market
- Equities
- RENX Stock
- News Renalytix Plc
- Renalytix Plc Announces the Stepped Down of Timothy Scannell as Independent Non-Executive Director